Atypical Hemolytic-Uremic Syndrome Clinical Trial
Official title:
An Observational, Non-Interventional, Multi-Center, Multi-National Study of Patients With Atypical Hemolytic-Uremic Syndrome (aHUS Registry)
Post-marketing safety data on patients treated and untreated with eculizumab or ravulizumab.
The study will capture post-marketing safety data on patients treated with eculizumab or ravulizumab. Additionally, the study will collect information on the progression of disease in all patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01193348 -
An Open-Label, Multi-Center Clinical Trial of Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome
|
Phase 2 | |
| Completed |
NCT01194973 -
An Open-label, Multi-center Clinical Trial of Eculizumab in Adult Patients With Atypical Hemolytic-uremic Syndrome
|
Phase 2 |